98%
921
2 minutes
20
Due to its invisible nature, individuals must make decisions around self-disclosing Inflammatory Bowel Disease (IBD). Existing reviews have explored stigma as a barrier to disclosing IBD; however, other factors potentially affecting disclosure decisions have not been recently reviewed. The current review sought to synthesise qualitative papers exploring the experiences of disclosure, and identify facilitators and barriers to disclosure, within IBD. A systematic search identified 34 journal articles, comprising 1,004 participants. Following critical appraisal, a thematic meta-synthesis was completed. (PROSPERO registration ID CRD42023481441). A total of six main themes relating to self-disclosure were identified: it's a stigmatised illness; a wish to conceal; difficulties discussing IBD; a need to disclose; balancing the need to disclose and the reluctance to disclose; and varied consequences to disclosure. Overall, the included studies were adequate quality; however, weaknesses in reflexivity were observed across a high proportion. This review highlights the complexity of disclosure decisions and describes how personal beliefs, social contexts, and previous experiences can influence these. Potential clinical implications, the impact for public health services, and the need for future research are discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12370872 | PMC |
http://dx.doi.org/10.1007/s10880-025-10079-z | DOI Listing |
Int J Nanomedicine
September 2025
The First Hospital of Hunan University of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, People's Republic of China.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease, the incidence of which continues to rise globally, and existing therapeutic options are limited by low drug bioavailability and systemic side effects. In this study, we systematically investigated the challenges of the special gastrointestinal environment of UC patients for oral drug delivery, such as extreme pH, degradation by digestive enzymes, metabolism of intestinal flora and obstruction of the intestinal mucosal barrier, and summarized the potential of plant-derived Exosome-like Nanovesicles (PELNs) as a novel delivery system. PELNs are produced by plant cells and mainly consist of proteins, RNA, lipids and plant active molecules.
View Article and Find Full Text PDFJ Surg Case Rep
September 2025
Department of Pediatric Gastroenterology and Hepatology, Bai Jerbai Wadia Hospital for Children, Acharya Dhonde Marg, Parel, Mumbai, Maharashtra 400012, India.
Metastatic Crohn's disease (MCD) is a rare extraintestinal manifestation of Crohn's disease (CD), particularly in pediatric patients. It refers to cutaneous involvement at areas distant and non-contiguous from the bowel. We present a boy with a 1.
View Article and Find Full Text PDFFront Med (Lausanne)
August 2025
Internal Clinic, 3rd Medical Faculty, Charles University and University Thomayer Hospital, Prague, Czechia.
Objectives: The absorption of conventional cholecalciferol may be impaired in patients with inflammatory bowel disease (IBD). The bioavailability and optimal dosing of buccally absorbable nanoemulsion vitamin D in this population remain unclear. This study aimed to compare the effects of buccal nanoemulsion and conventional oral vitamin D supplementation on serum 25-hydroxyvitamin D (25OHD) levels in patients with IBD.
View Article and Find Full Text PDFFront Med (Lausanne)
August 2025
Department of Nursing, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: Inflammatory bowel disease (IBD) is a chronic condition characterized by the need for highly individualized treatment plans, requiring patients to make numerous complex medical decisions. Shared decision-making (SDM) has proven effective in improving treatment outcomes, patient satisfaction, and adherence in IBD management; however, its clinical implementation remains challenging. In China, formal SDM nurse roles have not yet been established.
View Article and Find Full Text PDFBackground: Global evidence has observed that individuals with inflammatory bowel disease (IBD) are at a heightened risk of experiencing psychiatric disorders, which often coincide with a decrease in their quality of life.
Objective: To assess the prevalence of anxiety and depression symptoms and associated factors among patients with IBD.
Methods: An institutional-based cross-sectional study was conducted at Tikur Anbesa Specialized Hospital and Adera Medical Center.